Dr Mark Fendrick, University of Michigan, co-editor-in-chief, AJMC, moderates a discussion with Dr David Winston, section head of gastroenterology & hepatology, Cigna HealthCare of Arizona; Dr Steven Miller, chief medical officer, Express Scripts; and Dr Nezam H. Afdhal, associate professor of medicine, Harvard School of Medicine, chief of hepatology, director of Liver Center, Beth Israel Deaconess Medical Center.
Dr Mark Fendrick, University of Michigan, co-editor-in-chief, AJMC, moderates a discussion with Dr David Winston, director, gastroenterology and hepatology, Cigna; Dr Steven Miller, chief medical officer, Express Scripts; and
Dr Nezam H. Afdhal, associate professor of medicine, Harvard School of Medicine, chief of hepatology, director of Liver Center, Beth Israel Deaconess Medical Center.
The group begins to delve into their expertise with hepatology, and discusses the treatment innovations that are emerging in today’s healthcare landscape. They note the growing role of primary care physicians in hepatitis C treatment, and what impact this might have on the healthcare system.
HIV, Hepatitis C Testing Rates Remain Dismal Among Injection Drug Users
April 17th 2020Despite being at an increased risk for HIV and hepatitis C, persons who inject drugs (PWID) are tested at dismal rates for both: just 8.6% and 7.7%, respectively, according to data from 2010 to 2017. PWID who live in rural communities are more likely to face barriers to adequate testing and care for both diseases.
Read More
Dr Rebekah Gee Offers an Inside Look at Louisiana's Subscription Payment Model for HCV Drugs
May 7th 2019We speak with Dr Rebekah Gee, secretary of the Louisiana Department of Health about the subscription payment model for hepatitis C virus drugs that the state has entered into with Asegua Therapeutics, a subsidiary of Gilead Sciences.
Listen